The Filing Desk

Seres Therapeutics vs Yarrow Bioscience

Seres Therapeutics MCRB · Yarrow Bioscience YARW · Pharmaceuticals

Seres Therapeutics reported revenue of $1 million in fiscal 2025, 1.3 times Yarrow Bioscience's $1 million in fiscal 2025. Seres Therapeutics had an operating margin of -11910.1%, against -5219.1% at Yarrow Bioscience. Free cash flow was $1 million at Seres Therapeutics and −$33 million at Yarrow Bioscience.

Side by side

Seres TherapeuticsYarrow Bioscience
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$1M
Revenue growth—13.8%
Revenue growth a year, last 5 years−52.5%−50.9%
Gross margin——
Operating margin−11,910.1%−5,219.1%
Net margin721.9%−4,646.1%
Free cash flow$1M−$33M
Free cash flow margin109.6%−5,811.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.2%0.4%
Last close$1.33$14.23
P/E at the last close——
Insider trades, last 12 monthssold $10,043—
Piotroski F-score5 of 83 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Seres TherapeuticsYarrow Bioscience
Operating margin
Percent of revenue
Seres TherapeuticsYarrow Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Seres TherapeuticsYarrow Bioscience

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Seres Therapeutics and Yarrow Bioscience pages.